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SUMMARY
Oncogenic Kras initiates pancreatic tumorigenesis, while subsequent genetic events shape the
resultant disease. We show here that concomitant expression of KrasG12D and haploinsufficiency
of the Smad4/Dpc4 tumor suppressor gene engenders a distinct class of pancreatic tumors, mucin-
ous cystic neoplasms (MCNs), which culminate in invasive ductal adenocarcinomas. Disease evolves
along a progression scheme analogous to, but distinct from, the classical PanIN-to-ductal adeno-
carcinoma sequence, and also portends a markedly different prognosis. Progression of MCNs is
accompanied by LOH of Dpc4 and mutation of either p53 or p16. Thus, these distinct phenotypic
routes to invasive adenocarcinoma nevertheless share the same overall mutational spectra. Our
findings suggest that the sequence, as well as the context, in which these critical mutations are
acquired helps determine the ensuing pathology.INTRODUCTION
Preinvasive neoplasms of the pancreas are among the
most common and potentially lethal of the epithelial malig-
nancies (Kozuka et al., 1979; Andea et al., 2003). These
precursors to infiltrating pancreatic ductal adenocar-cinomas (PDAs) typically progress through a series of
histologically and genetically defined stages, collectively
termed pancreatic intraepithelial neoplasias (PanINs). Re-
sistant to all current forms of chemical and radiotherapies,
PDA has a cumulative 5 year survival rate of less than 5%
(Warshaw and Fernandez-del Castillo, 1992).SIGNIFICANCE
Detecting preinvasive lesions and accurately determining their propensity for malignant transformation represent
critical challenges for the practicing oncologist. For some malignancies, such as pancreatic cancer, resection at
the preinvasive state may represent the only currently viable hope for cure. However, such interventions are not
without risks or costs. Thus, determiningwhen to intervene can be as important as the intervention itself. For cystic
neoplasms of the pancreas, this diagnostic dilemma is particularly acute. Although less likely to transform and
progress than their more classical intraepithelial counterparts, once cystic neoplasms have invaded and metasta-
sized, they can be as lethal. We present here a genetically defined animal model of mucinous pancreatic cystic
neoplasms that should enable detailed exploration of these critical issues.Cancer Cell 11, 229–243, March 2007 ª2007 Elsevier Inc. 229
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KrasG12D and Smad4 Deletion in Pancreatic CancerSignificant progress has been made in elucidating the
genetic pathways to PDA (Hruban et al., 2000, 2001).
Mutations in KRAS occur early in disease progression
and are found in greater than 90%of invasive carcinomas;
principal tumor suppressor gene mutations include
CDKN2A/INK4A (95%), TP53 (>75%), and DPC4/
SMAD4 (55%). Systematic analysis of pathways of
imputed importance in pancreatic oncogenesis can be ac-
complished by engineering these mutations individually,
and in combination, into the laboratory mouse. Such ex-
periments have established that endogenous KrasG12D
expression can initiate pancreatic tumorigenesis and
that the resultant preinvasive lesions progress to invasive
and metastatic PDA (Hingorani et al., 2003). Concomitant
KrasG12D and Trp53R172H expression results in acceler-
ated development of PDA with clinical, histological, and
genetic features that closely recapitulate those of the hu-
man disease (Hingorani et al., 2005). Disease is also has-
tened in the context of p16Ink4a deficiency (Bardeesy et al.,
2006) and biallelic p16Ink4a/p19Arf deletion (Aguirre et al.,
2003), albeit with distinct clinical and histopathologic fea-
tures. In each of these cases, however, abrogation of ad-
ditional tumor suppressor gene pathways is not required,
suggesting that there may be unique genetic routes to
pancreatic cancer with corresponding and definable dis-
ease characteristics.
Distinct adenoma-to-carcinoma sequences exist in the
pancreas in which invasive adenocarcinomas arise from
cystic neoplasia (reviewed in Adsay, 2005; Hruban,
2006). Although the majority of cystic lesions in the pan-
creas are benign, a significant fraction represent preinva-
sive or focally invasive neoplasms, and with the advent
and wider use of increasingly sophisticated imaging
modalities, cystic neoplasms are being identified more
frequently, often as incidental findings (Fernandez-del
Castillo et al., 2003). Cystic neoplasms fall into two broad
categories, intraductal papillary mucinous neoplasms
(IPMNs) and mucinous cystic neoplasms (MCNs). Al-
though several clearly distinct morphological and clinical
criteria have been elaborated to distinguish these two
categories of neoplasms (Hruban et al., 2004; Maitra
et al., 2005), much less is known about the genetic events
that underlie their formation and progression to invasive
disease. When they do progress, IPMNs give rise most
frequently to colloid carcinomas, but also to tubular (duc-
tal) adenocarcinomas (Adsay et al., 2002). MCNs progress
through preinvasive stages involving low-, moderate-, and
high-grade dysplasia (or carcinoma in situ), culminating in
invasive ductal adenocarcinomas. Thus, there appear to
bemultiple distinct histological as well as genetic trajecto-
ries for the evolution of neoplastic events in the ductal
epithelium of the pancreas.
Intriguingly, the available data suggest that the overall
profile of genetic events found in the development and
progression of MCNs is highly congruous with that seen
in the more conventional PanIN-to-PDA sequence.
Nevertheless, resection of invasive carcinomas asso-
ciated with MCNs portends a dramatically more favorable
prognosis, with long-term survival rates of 50%–60%230 Cancer Cell 11, 229–243, March 2007 ª2007 Elsevier Inc.(Hruban, 2006). The reasons for the stark differences in
histopathology and clinical behavior are unclear but are
of obvious potential importance for the management of
each entity.
We present here an exploration of the effects of dis-
rupted TGFb signaling on shaping disease initiated by
KrasG12D. We find that concomitant heterozygous deletion
of Smad4/Dpc4 in the murine pancreas results in the elab-
oration of macroscopic MCNs that closely resemble the
human disease. In addition to elucidating key features of
this challenging class of pancreatic cystic neoplasms
and providing a means to probe the mechanisms under-
lying their distinctive properties, the findings also help
illuminate general principles about the divergent pathoge-
netic routes to invasive ductal adenocarcinoma of the
pancreas.
RESULTS
Targeting KrasG12D and Smad4/Dpc4 Deletion
to the Murine Pancreas
Previous studies involving constitutive heterozygous dele-
tion of Smad4 revealed no overt pathology in the pancreas
(Takaku et al., 1998, 1999; Xu et al., 2000). We too found
that targeted heterozygous or homozygous deletion of
Smad4/Dpc4 in the murine pancreas did not disrupt nor-
mal pancreatic development or alter parenchymal archi-
tecture (Figure S1 in the Supplemental Data available
with this article online). Moreover, Dpc4flox/+;Cre and
Dpc4flox/flox;Cre animals did not manifest clinical signs of
pancreatic insufficiency, had normal fasting blood glu-
cose levels, gained weight normally (data not shown),
and had a normal life span (see below). The synthetic func-
tions of both the exocrine and endocrine compartments of
the pancreas also appeared to be intact (Figure S1).
We surmised, therefore, that initiation of preinvasive
disease in the pancreas would again require endogenous
expression of oncogenic KrasG12D (Hingorani et al., 2003).
We targeted oncogenic Kras expression and conditional
Smad4/Dpc4 deletion to progenitor cells of the murine
pancreas using a strategy similar to that described previ-
ously (Figure 1A) (Hingorani et al., 2003, 2005). Deletion of
exon 8 of the floxed Smad4/Dpc4 allele results in a frame-
shift, rapid degradation of the truncated transcript, and no
evidence of protein expression by immunoblot (Yang
et al., 2002; and see below).
We first targeted the desired genetic events to
Pdx-1-expressing cellular compartments. KrasLSL-G12D/+;
Dpc4flox/+;Pdx-Cre animals had a median survival of ap-
proximately 8 months, significantly shorter than control
animals. At necropsy, we found that these animals devel-
oped large, space-occupying gastric neoplasms that
were the proximal cause of death (data not shown).
Many of these gastric tumors were locally invasive and
metastatic squamous cell carcinomas. Interestingly, while
the pancreata from these animals manifested preinvasive
(PanIN) lesions as expected, they also revealed a distinct
class of macroscopic cystic lesions, primarily of the body
Cancer Cell
KrasG12D and Smad4 Deletion in Pancreatic CancerFigure 1. Targeting Endogenous KrasG12D Expression and Dpc4/Smad4 Deletion to the Mouse Pancreas
(A) Endogenous KrasLSL-G12D/+ and Dpc4flox/+ alleles are conditionally activated and deleted, respectively, upon tissue-specific exposure to Cre re-
combinase. Specific PCR analyses (inset, small blue arrows) permit genotyping of animals and detection of the respective ‘‘1LoxP’’ product after
recombination of each targeted allele.
(B) Survival of KrasLSL-G12D/+;Dpc4flox/+;p48Cre (KD) mice is significantly less than that ofDpc4flox/+;p48Cre (D) animals and of mice carrying only one or
none of the various alleles (controls) (p < 0.001, log rank test, for each pairwise combination). Survival of KD animals is not significantly different from
that of KrasLSL-G12D/+;p48Cre (K) mice.
(C) Survival of KrasLSL-G12D/+;Dpc4flox/flox;p48Cre (KDD) mice (8 months) is significantly decreased compared to controls, Dpc4flox/flox;p48Cre (DD), KD,
and K mice (p < 0.001, log rank test, for each pairwise combination).and tail of the organ (discussed further below), which had
not been seen in our prior models.
Concomitant KrasG12D Expression and Smad4/Dpc4
Haploinsufficiency Induce Pancreatic Cystic
Neoplasms
The gastric tumors arising in KrasLSL-G12D/+;Dpc4flox/+;
Pdx-Cre animals undoubtedly reflected the extrapancre-
atic expression of Pdx-1 (Offield et al., 1996). We therefore
targeted expression of the relevant mutant alleles to the
p48-specific compartment, which is more tightly confined
to the pancreas (Kawaguchi et al., 2002). KrasLSL-G12D/+;
Dpc4flox/+;p48Cre/+ (KD) animals also had a shortened life
span compared with various controls, although median
survival was not significantly different from that of
KrasLSL-G12D/+;p48Cre/+ (K) mice (Figure 1B). In younger
animals, the pancreatic parenchyma and associated syn-
thetic functions of KD animals were largely preserved
(Figure S1). As the animals aged, however, they frequently
developed palpable, compressible masses, usually in the
left lower quadrant of the abdomen (Figure 2C). At nec-
ropsy, KD mice did not manifest gastric pathology but in-
stead had macroscopic, mucinous cystic lesions in thebody and tail of the pancreas (Figures 2A–2E). These
animals also manifested a lower overall burden of
macroscopic metastatic disease than KrasLSL-G12D/+;
Trp53LSL-R172H/+;Cre (KP) mice (Hingorani et al., 2005)
(Table S1). The head of the pancreas in these animals
was characteristically micronodular and sometimes con-
tained firm masses, as can be seen with expression of
activated Kras alone (Hingorani et al., 2003); occasionally,
the pancreatic head also revealed small visible cystic
lesions (Figure 2A) but typically did not contain the large,
multilocular cysts encountered in the tail and body. In-
deed, the latter cysts could be as large as 2–3 cm in diam-
eter and yield up to several milliliters of fluid. The generally
serous cystic fluid also occasionally contained hemor-
rhagic material and cellular debris (Figure 2E).
Histologic Progression of Murine MCNs
The pancreata from KD animals contained preinvasive
lesions consistent with the murine PanIN (mPanIN) pro-
gression scheme (Hruban et al., 2006). Importantly, and
as described in previous models (Hingorani et al., 2003,
2005), these mPanIN lesions did not involve the main
pancreatic duct or large branches (Figure 2N), but ratherCancer Cell 11, 229–243, March 2007 ª2007 Elsevier Inc. 231
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KrasG12D and Smad4 Deletion in Pancreatic CancerFigure 2. MCNs in KD Mice Faithfully Mimic the Human Disease
(A) Characteristic multilocular cystic lesion in the tail of the pancreas (arrows). The head of the pancreas in this animal also contained a small cyst
(arrowhead).
(B) Multilocular cystic lesions (arrows) involving the body and tail of the pancreas.
(C) Palpable, compressible abdominal mass (dotted line) resulting from large hemorrhagic cyst in the tail of the pancreas (see [D] and [E]).
(D and E) Hemorrhagic cystic neoplasm (‘‘chocolate cyst’’) in the tail of the pancreas before (D) and after (E) dissection. Note the thickened wall
(arrowheads) and presence of nodules (arrows) within the cyst.
(F) Human MCNs revealing mucin-filled epithelial cell lining.
(G) Cluster of murine cystic lesions lined by mucinous columnar epithelium.232 Cancer Cell 11, 229–243, March 2007 ª2007 Elsevier Inc.
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KrasG12D and Smad4 Deletion in Pancreatic Cancerthe peripheral ductules where human PanINs are also
thought to originate. Interestingly, even by 7–8 months
of age, the PanINs observed in KD animals were largely
low grade; this contrasts with the significant numbers of
PanIN-2 and high-grade PanIN-3 lesions that develop by
this age in KrasLSL-G12D/+;p48Cre/+ littermates and in previ-
ously described KrasLSL-G12D/+;Cre (Hingorani et al., 2003)
and KP (Hingorani et al., 2005) mice. In addition to low-
grade PanINs, cystic neoplasms were also noted micro-
scopically throughout the KD pancreata, although they
were particularly prominent in the body and tail of the or-
gan. The cystic lesions were lined by columnar, mucin-
filled epithelial cells (Figures 2G–2K) and also appeared
not to involve the main pancreatic duct (Figure 2N), nor
did they contain significant papillary projections into the
lumen, which are more characteristic of IPMNs. The neo-
plasms showed nuclear and architectural evidence of pro-
gression from low-grade (Figures 2G–2I), to moderate
(Figure 2J), to high-grade (Figure 2K) dysplasia. The sur-
rounding stroma was frequently very cellular and con-
tained spindle-shaped cells with distinctive ‘‘wavy’’ nuclei
(Figures 2I–2K and see below), all features seen in human
MCNs (Figures 2F, 2L, and 2M). Finally, the abundant
mucin content of the cystic epithelium could be demon-
strated by reaction with Alcian blue (Figure 3A), and the
ductal phenotype of the epithelial cells was confirmed
by expression of CK-19 (Figure 3B).
The stromal compartment of human MCNs characteris-
tically demonstrates ‘‘ovarian-type’’ features, a reference
to their compact growth pattern and wavy nuclei. These
distinctive stromal elements are typically found in focal
collections, usually in close association with the MCNs,
and are notably not seen with IPMNs. The stromal cells
also express characteristic markers, such as the proges-
terone receptor (PR) in 50%–75% of cases, and the estro-
gen receptor (ER) in approximately 25% of cases (Adsay,
2005). Many regions of the stroma in association with the
mucinous cystic lesions of compound mutant animals
possessed ‘‘ovarian-like’’ features (Figures 2I–2K and
Figure 3). The stromal cells also showed strong nuclear
expression of PR (Figure 3C) and, less frequently, ER
(Figure 3D). In addition, spindle-like cells were also noted
strongly expressing desmin (Figure 3E) and smooth mus-
cle actin (Figure 3F), markers also found in the stroma of,
though not specific for, MCNs in humans. We note that
cystic lesions do also occasionally arise in previously de-
scribed KrasLSL-G12D/+;Pdx-1-Cre and KrasLSL-G12D/+;
p48Cre/+ animals (Hingorani et al., 2003). Importantly,those cysts do not possess ovarian-like stroma, nor do
the stromal cells express PR (Figure 3G) or ER (Figure 3H).
Attenuated Proliferation of Ductal Epithelium
in MCNs
We have previously described the increased proliferation
of ductal cells in PanIN lesions that occurs with endoge-
nous KrasG12D expression (Hingorani et al., 2003) and
the intriguing apparent resistance of the acinar and islet
cell compartments to such effects. The PanINs that de-
velop in KD animals have a similarly elevated proliferative
index as assessed by nuclear Ki-67 expression: 17.4% ±
0.6% of PanIN ductal cells express Ki-67, while less
than 2% of acinar and 1% of islet cells are proliferating
(Figure S3). Normal-appearing ductal cells in KD animals
have a proliferative index of less than 0.3%, as was also
found previously (Figure S3B). Intriguingly, although the
ductal cells in MCNs demonstrated a higher proliferative
index (2.0% ± 0.5%) than their normal counterparts
(Figure S3C), this rate was nevertheless substantially at-
tenuated as compared with cells in PanIN lesions. Thus,
differentiation toward a cystic neoplasm may restrict the
proliferative stimulus provided by oncogenic Kras. As
the animals continue to age and the MCNs develop
higher-grade dysplasia, their proliferative index also
increases (10.4% ± 2.2%), particularly when found in
association with invasive disease (Figure S3D).
Homozygous Deletion of Smad4/Dpc4 Accelerates
Development of MCNs
KrasLSL-G12D/+;Dpc4flox/flox;p48Cre (KDD) animals suc-
cumbed earlier than their heterozygous counterparts
(Figure 1C), with highly prevalent, macroscopic cystic
lesions of the pancreas (Figure S2) similar to those
described above, suggesting that LOH of Dpc4/Smad4
contributes to disease progression (and see below). We
note that both KD (median survival 15 months) and KDD
animals (median survival 8 months) lived significantly
longer than previously describedKPmice (median survival
5 months; Hingorani et al., 2005). The latter cohort devel-
oped aggressive, locally invasive, and widely metastatic
PDA highly reminiscent of human PDA. In contrast, the le-
sions in KD (Table S1) and KDD animals were less likely to
invade or metastasize (Table S2). In particular, macro-
scopically evident metastases to the liver (35% and 18%
versus 55%) and lung (18% and 0% versus 44%) were
markedly less frequent in KD and KDD animals, respec-
tively, as compared with KP mice (Hingorani et al.,(H) Mucinous epithelia of adjacent cysts separated by a stromal septum demonstrating moderate-grade (top) and low-grade (bottom) dysplasia.
Arrows indicate goblet-like cells.
(I) Cystic lesion with low-grade mucinous epithelium and surrounding highly cellular stroma. Note the dense growth and ‘‘wavy’’ nuclei of the stromal
cells.
(J) Cystic lesion showing moderate atypia and surrounding highly cellular stromal compartment.
(K) Cystic lesion showing high-grade dysplasia with areas of focally invasive carcinoma (arrows).
(L–N) Human cystic neoplasms with low-grade (L), moderate-grade (M), and high-grade dysplasia (N).
(O and P) Invasive adenocarcinoma in association with cystic neoplasm at the tail of the pancreas. Note region of focal microscopic invasion extend-
ing from cyst to frankly invasive carcinoma ([O], box) and ([P], arrowheads).
(Q) Main pancreatic duct is characteristically uninvolved by preinvasive disease and appears histologically normal. Scale bars, 50 mm.Cancer Cell 11, 229–243, March 2007 ª2007 Elsevier Inc. 233
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KrasG12D and Smad4 Deletion in Pancreatic CancerFigure 3. Characteristics of the Epithe-
lial and Stromal Compartments of Mu-
rine MCNs
(A) Alcian blue stain revealing abundant apical
mucin in cystic epithelial cells.
(B) Cytokeratin-19 expression in epithelial cells
lining a cyst. st, highly cellular stroma underly-
ing the cystic neoplasm.
(C and D) Nuclear expression of PR ([C], ar-
rows) and ER ([D], arrows) in the stroma of dis-
tinct MCNs.
(E) Strong expression of desmin in stromal cells
within a focus of invasion (asterisk).
(F) Stromal cells associated with an MCN ex-
pressing smooth muscle actin (asterisk). Note
the wavy shape of the stromal nuclei.
(G and H) Lack of ‘‘ovarian-type’’ features and
absence of PR (G) and ER (H) expression in the
stromal cells (st and arrowheads) associated
with a spontaneous cystic lesion arising
in a KrasLSL-G12D/+;p48Cre animal. Scale bars,
20 mm.2005). A lower propensity for invasion and metastasis is
also seen with human MCNs as compared with ductal ad-
enocarcinomas not arising in association with a cystic
neoplasm.
Several criteria confirmed that the invasive lesions seen
in the setting of the murine MCNs arose from the cystic
neoplasms and not from the PanIN-PDA route. First, serial
sectioning of the pancreata revealed multiple areas of
direct microscopic invasion fromMCNs into the surround-
ing parenchyma (Figures 2 and 4 and Figures S3 and S7).
Second, the PanIN lesions in the adjacent parenchyma
were invariably low grade (Figure S7). Third, although
the metastatic lesions that developed in KD and KDD an-
imals were clearly from ductal adenocarcinomas, they
also reconstituted the cystic architecture of the primary le-
sions with striking fidelity, including demonstrating dis-
crete stages of low, moderate, and high-grade atypia in
the cystic epithelium (Figure S4). Metastases from the
classical glandular PDAs that arise in KP mice similarly
recapitulate the glandular features of their primary car-234 Cancer Cell 11, 229–243, March 2007 ª2007 Elsevier Inc.cinomas (Figure S4 and Hingorani et al., 2005). Fourth,
xenografts of primary cell lines derived from these invasive
carcinomas also recapitulated both the glandular and
cystic features of their origin (data not shown). Finally,
the prolonged survival seen in these animals is consistent
with the behavior of invasive adenocarcinomas arising
from MCNs as opposed to PanINs, as is also found in pa-
tients. Collectively, the properties and histologic features
of the murine cystic neoplasms described here faithfully
recapitulate human MCNs. Although we considered
the possibility that the lesions represent branch-duct
IPMNs that have arisen in more distal portions of the duc-
tal tree, the overall findings are more characteristic of
MCNs (see below).
Signaling Pathways in Murine MCNs
A number of signaling pathways are aberrantly activated in
human PanINs and PDA and similarly dysregulated in their
murine counterparts (reviewed in Leach, 2004). Much less
is known, however, about pathways and potential
Cancer Cell
KrasG12D and Smad4 Deletion in Pancreatic CancerFigure 4. Molecular Characterization of Tumor Progression of Cystic Neoplasms in KD and KDD Animals
(A) Evidence of recombined Kras allele (1LoxP) in primary cell lines prepared from matched sets of pancreatic and metastatic tissues. WT, wild-type.
Cell lines were prepared from the following tissues: H, head of pancreas; T, tail of pancreas; Liv, liver metastasis; A, ascites.
(B) A recombinedDpc4 allele was detected in all primary cell lines (top panel). Distinct PCRs identify the recombined (1LoxP) as well as the conditional
(cond) and wild-type (WT) alleles, respectively (see Figure 1).
(C) Immunoblot analyses of primary cell lines.
(D) RT-PCR analyses of indicated mRNAs in primary cell lines. Cell lines with complete recombination of conditional Dpc4 allele show evidence of
degraded transcript (e.g., KD#1), whereas those still retaining the WT and/or conditional (unrecombined) Dpc4 allele preferentially reveal the full-
length transcript by PCR of reverse-transcribed message (e.g., KD#2).
(E and F)Methylation-specific PCRof p16Ink4a (E) and p19Arf (F) loci in primary cell lines. (), negative control DNA from normal murine colon (neverthe-
less demonstrates some methylation of Ink4a locus); (+), positive control from in vitro methylated DNA.
(G–J) Immunohistochemical analyses of Dpc4 in amurineMCN. Regions indicated by arrows in (G) are shown at higher power in (H)–(J). Note retention
of Dpc4 in stromal cells (arrowheads). Scale bars, 50 mm.Cancer Cell 11, 229–243, March 2007 ª2007 Elsevier Inc. 235
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We therefore examined the expression of a number of re-
ceptors and signaling proteins in preinvasive, invasive,
and metastatic cystic neoplasms of KD and KDD animals.
ErbB1 (Egfr) and ErbB2 (Her2/neu) are upregulated in
these murine MCNs and invasive carcinomas (Figure S5).
High levels of Egfr expression persisted in invasive (Fig-
ure S5C) and metastatic lesions (data not shown), in con-
trast to the decreased expression that accompanied dis-
ease progression in KP animals (Hingorani et al., 2005).
Shh was also consistently overexpressed, diminishing
somewhat in metastases (Figures S5G–S5I). Strong pErk
expression could be seen in dysplastic regions of the cys-
tic epithelium, but not in regions retaining cuboidal mor-
phology (Figures S5J and S5K). Robust expression could
also be seen in invasive components but was typically re-
stricted to the periphery of metastatic lesions (Figure S5L).
Finally, Hes1, an indicator of Notch pathway activation,
was aberrantly expressed in some, though not all, regions
of dysplastic epithelium (Figure S5M); expression levels
increased dramatically with the degree of dysplasia and
persisted in invasive disease (Figures S5N and S5O).
Thus, Hes1may be a useful marker of more advanced dis-
ease. The level of Hes1 expression was also notably more
marked than that in the previously describedKrasLSL-G12D/+;
Cremodel (Hingorani et al., 2003), perhaps reflecting a link
between the TGFb and Notch signaling pathways (Zavadil
et al., 2004).
Genetic Progression of Murine MCNs
To attempt to define the additional genetic events required
for progression of these murine MCNs, we isolated
primary neoplastic cell lines from several pancreata and
associated metastatic lesions by methods described pre-
viously (Hingorani et al., 2005). Matched portions of each
resected specimen were processed in parallel for histo-
logic and immunohistochemical analyses. Although it is
formally possible that the isolated cell lines contain both
preinvasive and invasive cells, as the cystic masses from
which they were derived contained both preinvasive and
invasive components, it was nevertheless clearly possible
to discern critical genetic events associated with disease
progression.
Several notable properties of the isolated primary cells
were apparent. First, these neoplastic cell lines expanded
more slowly than those from KP animals. Second, our
overall success rate in establishing these lines (60%–
70%) was lower than that of the previous model (>90%).
Finally, these cells maintain a preference for growth on
specialized substrates such as collagen, while KP cells
are quickly able to grow equally well on plastic or collagen.
In a representative panel of primary cell lines isolated
from KD and KDD animals, we characterized genetic
events, transcript levels, and protein expression of several
critical loci (Figure 4 and Table S3). We first confirmed that
each of the isolated tumor cell lines contained the recom-
bined oncogenic Kras allele (Figure 4A). Surprisingly, at
least one matched set of primary pancreatic and liver me-
tastasis cells (KDD#1) had also lost the wild-type Kras236 Cancer Cell 11, 229–243, March 2007 ª2007 Elsevier Inc.locus, suggesting the possibility that, in the setting of
oncogenic KrasG12D, the remaining wild-type allele may
have a tumor-suppressive effect (Zhang et al., 2001). As
expected, the floxed Dpc4 allele was also recombined
(i.e., deleted) and loss of the wild-type allele was observed
in cells from several Dpc4flox/+ mice (example KD#1,
Figure 4B). There were rare instances of incomplete re-
combination of the Dpc4 locus (see examples KD#2 and
KDD#3, Figure 4B).KD#2 was derived from the pancreatic
tail cyst shown in Figures 2D and 2E, histological analysis
of which revealed the presence of a large cystic epithelial
neoplasm in association with rare foci of microscopic in-
vasion (data not shown).
Immunoblot analysis confirmed that Dpc4 expression
was frequently lost in cells isolated from KD animals, con-
sistent with LOH of this locus (Figure 4C). Many cell lines
did not express p16Ink4a, although they did usually retain
expression of p19Arf. The mechanism(s) by which these
genes were effectively silenced was examined first by
sequencing their respective cDNAs (see Experimental
Procedures for details). The inability to isolate detectable
message for p16Ink4a and full-length message for Dpc4
by RT-PCR from several of the lines explained their lack
of protein expression (KDD#2 and KD#1, Figure 4D). The
matched set of cell lines expressing high levels of p16
(KDD#1) had a uniform nonsense mutation in Trp53. Con-
versely, the samples that lacked significant p16 levels
were found to have wild-type Trp53. Trp53 levels were
induced by DNA damage in cells with wild-type Trp53,
but not in those carrying mutant Trp53, confirming disrup-
tion of the pathway (Figure S6). Nomutations were discov-
ered in Cdk4, or in Dpc4 when the full-length cDNA was
recoverable.
The major mechanisms of Cdkn2a/Ink4a (p16Ink4a) si-
lencing in human pancreatic cancer include promoter
methylation and deletion of the locus, with missense mu-
tations being much less prevalent. Methylation-specific
PCR (MSP) analyses revealed frequent methylation of
the p16Ink4a promoter region in primary tumor cell lines
(Figure 4E). In some instances, only a methylated band
was recovered, consistent with epigenetic silencing of ex-
pression (for example, KD#1, Figure 4E). We were unable
to amplify the Cdkn2a/Ink4a locus at all in other cell lines
(KDD#2-H, T and A, Figure 4E), providing an alternative
mechanism for the loss of expression; specific PCR di-
rected against another region of the locus gave the
same result (data not shown). MSP for the p19Arf locus,
which is physically contiguous with that of p16Ink4a,
showed no evidence of methylation (Figure 4F). Thus, pro-
moter methylation was specific for the p16Ink4a locus, and
p16Ink4a expression was extinguished by a combination of
epigenetic silencing and genomic deletion.
To confirm that LOH of Dpc4 had occurred in vivo, and
not as a result of the in vitro isolation of cell lines, we per-
formed immunohistochemical analyses of resected tissue
specimens. We found that Dpc4 expression was retained
in preinvasive cystic neoplasms in KD animals, but lost in
adjacent areas of invasive carcinoma and metastases
(Figures 4G–4J, Figure S7, and data not shown).
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(A) Proliferation of primary cell lines in the presence (open symbols) or absence (closed symbols) of TGFb.
(B and C) Induction of EMT by TGFb requires Dpc4/Smad4. The presence of actin-stress fibers (B) and surface E-cadherin expression (C) were eval-
uated by reaction with phalloidin green and specific antibody, respectively. Cells were also stained with DAPI (blue). Scale bars, 20 mm.Unfortunately, the available reagents do not permit similar
studies for p16 with fidelity.
Finally, we performedmeasures of genomic instability in
primary tumor cell lines derived from KDD mice. We had
previously discovered a high degree of both numerical
(simple) and structural (complex) genomic instability in
the tumors and pancreatic cell lines from KP animals, pro-
cesses that may have contributed to their highly invasive
and metastatic nature (Hingorani et al., 2005). We found
that centrosomal amplification, the presumptive proximal
cause of losses and gains of whole chromosomes, was
demonstrably less extensive in KDD cells than in KP cellsC(Figure S8). Preliminary analyses also revealed fewer
nonreciprocal translocations, the hallmarks of complex
chromosomal instability (data not shown). Interestingly,
in KDD cells with a nonsense mutation in Trp53, the extent
of centrosomal amplification was intermediate between
that of KDD cells containing wild-type Trp53 and KP
ductal cells (Figure S8).
Smad4 Is Essential, but Not Sufficient, for Effective
Growth Inhibition by TGFb
To begin to elucidate the mechanistic basis for the unique
phenotype observed in Smad4/Dpc4 mutant animals,ancer Cell 11, 229–243, March 2007 ª2007 Elsevier Inc. 237
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several measures of neoplastic behavior. As expected,
KrasLSL-G12D/+;p48Cre/+ pancreatic ductal cells (K#1)
were efficiently growth arrested by TGFb (Figure 5A).
The proliferation of KP ductal cells was also significantly
diminished by exposure to TGFb, completely arresting
growth in one cell line (KP#1) and slowing it in another
(KP#2) (Figure 5A). Interestingly, neither KDD nor KD cells
that had subsequently undergone LOH at the Smad4/
Dpc4 locus could be completely growth inhibited by
TGFb, although one cell line (KDD#1) was partially in-
hibited (Figure 5A). We note that the latter cells had ele-
vated resting levels of both p16Ink4a and p19Arf, a possible
compensatory result of the spontaneously acquired Trp53
mutation. Similarly elevated levels of p16Ink4a and p19Arf
are found in cell lines with engineered point mutation of
Trp53 (Figure 4 and Hingorani et al., 2005).
Not all KP ductal cells were susceptible to the growth
effects of TGFb (Figure S9A). As discussed further below,
although these cells (KP#3) retained expression of key
mediators of TGFb effects, including Smad4 and
p15Ink4b, the latter failed to be induced by TGFb (Fig-
ure S9B). Thus, it appears that the ability of TGFb to
Figure 6. TGFb Effects on the Expression and Activities of
Cell-Cycle Regulators in Primary Ductal Cell Lines
Cells were treated with TGFb for the indicated times (hr), and levels of
p15, p16, p21, and c-mycwere analyzed by immunoblot. The specific-
ity of the c-myc band was confirmed by the known decrease in re-
sponse to DNA-damaging agents such as doxorubicin (Dox). Cdk4
and Cdk2 kinase activities were measured in cells incubated with (+)
or without () TGFb; control assays were performed with rabbit
serum (IgG).238 Cancer Cell 11, 229–243, March 2007 ª2007 Elsevier Inc.induce growth arrest in primary pancreatic ductal cells
requires intact Smad4-mediated signaling in addition to
other pathways (see below).
Induction of EMT and Enhanced Cell Migration
Requires Intact Smad4 Signaling
Epithelial-to-mesenchymal transition (EMT) denotes pro-
cesses thought to be crucial for invasion and metastasis
(Thiery, 2002). Members of the TGFb superfamily, and
principally TGFb1, contribute to this transformation. We
noted a dramatic induction of EMT by TGFb in several K
and KP ductal cell lines, manifested by a change from
a discretely epithelial population of cells to one with
the appearance of elongated, angular fibroblasts with pro-
jections and increased stress fiber formation (Figure 5B).
Surface expression of E-cadherin also decreased notably
in these cells (Figure 5C). TGFb had markedly less pro-
nounced effects on KDD ductal cells (Figures 5B and
5C), and on KD cells that had undergone LOH of Smad4
(data not shown), suggesting that Smad4 may also be
required for TGFb-induced EMT.
We also measured the ability of cells to migrate across
a wound in a monolayer. To distinguish the ability to com-
plete wound closure by migration as opposed to prolifer-
ation, we incubated cells with TGFb for 60 hr prior to
wound induction to ensure sufficiently robust growth inhi-
bition. Consistent with the ability to induce EMT, we found
that the otherwise negligible migration of KP cells was
greatly stimulated by TGFb (Figure S10). AlthoughKD cells
with LOH of Smad4/Dpc4 (KD#1) were capable of wound
closure, the process was not appreciably altered by expo-
sure to TGFb. Wound closure in this setting appeared to
be accomplished by proliferation across the gap rather
than migration per se, as was evident during close serial
monitoring. Moreover, the motility of one KDD cell line
(KDD#2) actually appeared to be inhibited by TGFb; al-
though these cells continued to proliferate in the presence
of TGFb, they appeared to pile up at the wound’s edge
rather than spread across the gap (Figure S10). These
findings underscore the independent mechanisms modu-
lating proliferation and migration and suggest that Smad4
signaling contributes substantively to the ability to migrate
in response to TGFb.
Cell-Cycle Mediators Chronicle the Response
to TGFb
To further explore the molecular basis for the cellular be-
haviors described above, we characterized the time
course of expression of several prominent cell-cycle reg-
ulators in response to TGFb. In cells that arrest effectively,
we observed both induction of p15Ink4b and prominent
levels of p16Ink4a (Figure 6; compare K#1, KP#1, KP#2,
and KDD#1 with KD#1). On the other hand, the absence
of either p15Ink4b induction (Figure S9; KP#3) or p16Ink4a
(KD#1) meant unbridled growth. Somewhat surprisingly,
the levels of c-myc did not change appreciably, for the
most part, in response to TGFb. The dynamic and counter-
balancing interplay between TGFb and the Myc proto-
oncogene contributes to modulating homeostasis of
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Cell Line Growth Arrest EMT Migration Smad4 Cdk2 Activity Cdk4 Activity p15 p16 Myc
KD #1     4 4 +  4
KDD #1 +    Y Y + + Y
KDD #2     4 4   Y
K #1 + + nd + Y Y + + Y
KP #1 + + + + YY Y + + Y
KP #2 + + nd + 4 4 + + 4
KP #3  + + + [[ 4/[ + + 4
Primary pancreatic ductal cells from K, KD, KDD, and KP animals were evaluated for the ability of TGFb to arrest growth, induce
EMT, stimulate migration, and affect Cdk2 and Cdk4 kinase activities and levels of myc. The presence or absence of detectable
levels of Smad4, p15, and p16 proteins is also noted.4, no change;[, increased; Y, decreased.tissue growth and repair responses in many contexts (Sie-
gel and Massague, 2003). In the primary cell lines studied
here, however, c-myc levels did not correlate with prolifer-
ative state (compare, for example, K#1 and KDD#2). Inter-
estingly, we did also note that p15Ink4b levels can be in-
duced even in the absence of Smad4 (see KDD#1,
Figure 6). Finally, in several cell lines p21Cip expression
was absent altogether, particularly in the setting of
Trp53 mutation, and in others the levels actually de-
creased, even in cells that were effectively growth ar-
rested. p27Kip expression did not change appreciably
over the course of TGFb exposure (data not shown).
Thus, the combined effects of p15Ink4b and p16Ink4a ap-
peared to be the most potent mediators of growth arrest.
Ultimately, the ability of cells to successfully surmount
the G1/S restriction point depends upon the integrated ef-
fects of various stimuli and suppressors on the enzymatic
activities of the critical cyclin-dependent kinases Cdk4
and Cdk2 (Sherr and Roberts, 2004). Basal Cdk4 kinase
activity was modest in general in the cell lines tested
and downregulated by TGFb in some but not in others
(Figure 6). A similar, though perhaps even more pro-
nounced profile was observed for Cdk2 activity, which
was often robust at baseline. Both Cdk4 and Cdk2 activ-
ities were notably decreased in every cell line that experi-
enced significant TGFb-induced growth inhibition but
continued unabated in those cell lines oblivious to the
presence of TGFb. In oneKP ductal cell line, the kinase ac-
tivities, Cdk2 in particular, were paradoxically stimulated
by TGFb (Figure S9B). Thus, the ability of TGFb to modu-
late proliferation in primary pancreatic ductal carcinoma
cell lines is reflected in the coordinated kinase activities
of Cdk4 and Cdk2 (summarized in Table 1).
DISCUSSION
Cystic Neoplasms of the Pancreas Provide Alternate
Routes to Invasive Carcinomas
Preinvasive neoplasms of the pancreatic ductal epithelium
include microscopic PanINs, the most common and best
characterized of the precursor lesions, as well as two dis-
tinct classes of macroscopic cystic neoplasia, IPMNs andMCNs. Beyond the histological features detailed above,
several intriguing clinical criteria further distinguish the
two categories of cystic lesions, including anatomic loca-
tion within the pancreas (central versus peripheral and
head versus body and tail), associated symptoms (rare
versus common), age at presentation (70–80 years versus
40–50 years), and prevalence by gender (roughly equal
versus >10:1 in favor of women) (reviewed in Tanaka
et al., 2006). From the limited available knowledge, the
critical genetic events underlying the development of
these two classes of cystic neoplasms also appear to be
distinct (Hruban, 2006). IPMNs have a much lower inci-
dence of mutations in KRAS and TP53 than the PanIN-
to-PDA carcinoma sequence and are essentially never
found to harbor mutations in DPC4/SMAD4 (Iacobuzio-
Donahue et al., 2000a). Approximately one-third of IPMNs
carry inactivating mutations in LKB1/STK11, the gene as-
sociated with Peutz-Jeghers syndrome (Sato et al., 2001).
A major subset of IPMNs show prominent intestinal differ-
entiation, exhibiting a ‘‘villous adenoma’’ growth pattern
and strong expression of intestinal differentiation markers
CDX2 and MUC2 (Adsay et al., 2004), which are typically
not features of MCNs. IPMNs have also been shown to
harbor mutations in PIK3CA, a gene often mutated in co-
lon cancer but not PDA (Schonleben et al., 2006). In con-
trast, the incidence of KRAS and TP53mutations in MCNs
is roughly the same as in PDA, and virtually all (90%)
invasive adenocarcinomas arising in association with an
MCN have mutations in DPC4/SMAD4 (Iacobuzio-Dona-
hue et al., 2000b). Thus, mutation of DPC4 appears to
be a distinguishing feature of human mucinous cyst-
adenocarcinomas as compared to IPMNs and their
associated carcinomas. Overall, the clinical presentation,
biological phenotype, histological appearance, and
genetic program of the cystic neoplasms in KD and KDD
animals all strongly resemble human MCNs.
Multiple Modes of TGFb Signaling Shape the Course
of Neoplastic Growth
The TGFb pathway influences epithelial tumorigenesis
by a number of mechanisms, including regulating cell-
autonomous effects, modulating immunosurveillance andCancer Cell 11, 229–243, March 2007 ª2007 Elsevier Inc. 239
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stromal interactions with the epithelium (Gorelik and Fla-
vell, 2002; Siegel and Massague, 2003; Bhowmick et al.,
2004b). Mutations in a number of critical elements in this
pathway have been identified across a range of malignan-
cies. The human aerodigestive tract, and gastrointestinal
epithelium in particular, is clearly reliant on an intact path-
way to suppress nascent neoplastic growth. Mutations in
TGFb pathway members are frequently encountered in
head and neck squamous cell carcinomas, gastric and co-
lorectal cancers, and juvenile polyposis (reviewed in Levy
and Hill, 2006). The effects of several of these mutations
have been confirmed in animal models (reviewed in Let-
terio, 2005). Interestingly, targeted mutation of TGFBIIR
in fibroblasts alone is sufficient to initiate tumorigenesis
in the gastric epithelium (Bhowmick et al., 2004a). Thus,
interrupting the dialog on either end between stromal
and epithelial cells can loosen the strictures on prolifera-
tion and polarity and unravel the architectural integrity of
the epithelium.
The frequent mutations in malignancies notwithstand-
ing, the TGFb pathway is also often complicit in advanced
stages of tumorigenesis. Tumor suppressing in certain
contexts, tumor promoting in others, TGFb signaling em-
bodies an inherent duality (Bierie and Moses, 2006). This
duality recalls the contrasting roles played by TGFb in pro-
moting cellular migration and organogenesis during early
development, and maintaining checks on unfettered
growth in mature organs. A similar dichotomy appears to
underlie the distinct features of the two pathogenetic
routes to invasive ductal carcinoma described here. Previ-
ous studies have elucidated distinctions between Smad-
dependent and independent signaling, as well as specific
Smad4-dependent and independent effects (for recent
examples see Levy and Hill, 2005; Valcourt et al., 2005;
reviewed in Derynck and Zhang, 2003). In the primary pan-
creatic ductal carcinoma cells studied here, both growth
inhibition and EMT appeared to require Smad4, and al-
though wound closure was possible in the absence of
Smad4, it could be further stimulated by TGFb in the set-
ting of an intact pathway.
The ‘‘canonical’’ TGFb pathway involves ligand binding
to type I and type II surface receptors; phosphorylation
of the receptor Smads, Smad2 and Smad3; and trans-
location to the nucleus of oligomeric receptor Smad
complexes with Smad4, which ultimately effect a context-
dependent program of transcriptional activation and re-
pression. More recently it has become clear that this linear
conceptualization of a sequential cascade represents an
oversimplification of what is, in fact, a complex web of
Smad-dependent and independent signaling pathways
orchestrated by the TGFb family of ligands (for reviews
see Derynck and Zhang, 2003; Massague et al., 2005).
These additional mechanisms of signaling include activa-
tion of other pathways by TGFb, such as MAPK, p38
MAPK, and JNK, as well as effects transduced by distinct
combinatorial Smad complexes, and even potentially
formation of complexes with other as yet unidentified
cofactors. Indeed, constitutive deletion of Smad2 is not240 Cancer Cell 11, 229–243, March 2007 ª2007 Elsevier Inc.functionally equivalent to that of Smad3, nor is deletion
of either receptor Smad equivalent to loss of Smad4
(reviewed in Weinstein et al., 2000). Moreover, in Smad4
null colon cancer cells, Smad2/3 complexes can never-
theless translocate to the nucleus (Fink et al., 2003). We
too have found that TGFb can induce efficient nuclear
translocation of Smad2/3 in KDD primary pancreatic duc-
tal cells (data not shown). Thus, the formation of the
Smad2/3/4 ternary complex appears to represent only
one arm of TGFb-induced receptor Smad signaling, and
both receptor Smads 2 and 3 likely participate in other
processes.
Very recently, another candidate for complex formation
with Smad2/3was identified, namely, transcriptional inter-
mediary factor 1g, or TIF1g (He et al., 2006). TIF1g is a nu-
clear factor that appears to compete with Smad4 for bind-
ing to activated Smad2/3 complexes. In erythroid cells,
TIF1g-Smad2/3 complexes mediate TGFb-induced differ-
entiation, while activated receptor Smads2/3 complexed
to Smad4 instead transduce the antiproliferative effects
of TGFb. Thus, TIF1g, or an analogous protein, would rep-
resent an ideal candidate to promote the distinct differen-
tiation program observed in Smad4-deficient pancreatic
ductal cells in the setting of the proliferative stimulus
provided by oncogenic KrasG12D, thereby resulting in the
elaboration of MCNs as opposed to PanINs. In this
Figure 7. A Model of Divergent Routes to Invasive Ductal
Adenocarcinoma of the Pancreas
The timing of specific tumor suppressor genemutations influences the
unique phenotypes and clinical behaviors of invasive ductal carcino-
mas that arise from MCNs and PanINs, respectively (see text for
details).
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balance toward an altered differentiation pattern (i.e., the
formation ofMCNs), while latermutation ofSmad4 (i.e., af-
ter Trp53) would no longer be able to affect differentiation,
but rather would only serve to remove a remaining imped-
iment to proliferation.
Pathways to Pancreatic Cancer
The collective results of our in vivo and ex vivo experi-
ments suggest a working model that may help reconcile
the distinct phenotypic and clinical behaviors of two fun-
damental routes to invasive ductal adenocarcinoma of
the pancreas (Figure 7). Our findingsmay also help explain
how these two disease pathways can share the same
overall mutational profile yet portend such dramatically
different prognoses for patients. Each route to invasive
disease is initiated by oncogenic mutation of Kras, which
represents the rate-limiting step and results in the forma-
tion of early PanIN lesions. Additional mutations in either
Trp53 or p16 promote progression along the canonical
PanIN pathway, resulting in high-grade lesions. On the
other hand, we found a relative paucity of advanced PanIN
lesions in KD animals even as cystic neoplasms began to
emerge. We propose that the early-stage PanINs that de-
velop in the setting of concurrent KrasG12D expression and
Dpc4 deletion are instead diverted along a distinct differ-
entiation pathway toward cystic neoplasms, concomitant
with attenuation of their proliferative rate (we cannot ex-
clude the possibility, however, that the MCNs arise de
novo and subsequently suppress PanIN progression by
some unknown mechanism). Subsequent LOH of Dpc4
hastens the progression of these MCNs, while also pre-
cluding the development of EMT. Conversely, as the
PanINs that progress through mutation of other TSG
pathways become invasive, they remain receptive to the
induction of EMT and enhanced migration by TGFb. Sub-
sequent mutation of Dpc4 at this late juncture in the
course of disease progression, as occurs in approximately
55% of human PDA, further unfetters proliferation, result-
ing in a highly invasive, metastatic, and ultimately lethal
disease. Of course, the timing of Dpc4 mutation may
also influence non-cell-autonomous processes, including
stromal and immune reactions, which may further contrib-
ute to shaping the distinct phenotypic and clinical behav-
iors of these two pathways to invasive disease.
The model provides a number of readily testable hy-
potheses. First, if indeed the altered differentiation toward
MCNs results from disrupting the balance between
Smad4-dependent and -independent signaling pathways,
then mutation of components further upstream in the
pathway should not engender the same phenotype. In
fact, mutations in TGFBRI and TGFBRII have been de-
scribed (albeit rarely) for classical PDA, but not for MCN-
invasive carcinoma. Thus, should concomitant mutation
of surface receptors for TGFb and expression of onco-
genic KrasG12D result in invasive ductal cancer, we would
anticipate a more conventional PDA phenotype. Second,
the pathology that ultimately develops in the setting of
multiple tumor suppressor gene mutations may reflectthe sequence in which the mutations occur in addition
to, or even preferentially over, the specific repertoire of
mutations. Thus, the model predicts that mutation of
Dpc4/Smad4 in the setting of pre-existing or concomitant
mutation of either Trp53 or p16Ink4a should result in con-
ventional PDA. Indeed, in preliminary analyses of
KrasLSL-G12D/+;Trp53LSL-R172H/+;Dpc4flox/+;Cre animals,
we have observed the development of classical ductal
adenocarcinoma of the pancreatic head with glandular
histology (D.A.T. and S.R.H., unpublished data), as is
seen in KP mice (Hingorani et al., 2005). Conversely, as
seen in the examples of spontaneous acquisition of
Trp53 or p16 mutations after deletion of Dpc4 described
here, cystic lesions of the body and tail should predomi-
nate. This hypothesis also helps explain the loss of
DPC4 expression in virtually all invasive adenocarcinomas
in association with MCNs, but only about half of classical
ductal adenocarcinomas (in which mutation of DPC4 is
known to occur late in the course of disease progression;
Wilentz et al., 2000). Ultimately, this conceptualization im-
plies that even detailed genetic diagnoses of pancreatic
cancer subtypes may be strictly insufficient for accurate
categorization of tumor type, molecular pathophysiology,
and prognosis, as the genetic profile does not reflect the
chronology of the mutations. Continuing comparative
analyses of the animal models now in hand for these two
unique pathways to invasive disease should help further
our understanding and management of the challenges
they each present.
EXPERIMENTAL PROCEDURES
Mouse Strains
Conditional Dpc4flox/+ (Yang et al., 2002), KrasLSL-G12D/+ (Jackson
et al., 2001), and p48Cre/+ (Kawaguchi et al., 2002) or Pdx-1-Cre (kindly
provided by Andrew Lowy and described in Hingorani et al. [2003])
strains were interbred to obtain KrasLSL-G12D/+;Dpc4/Smad4flox/+;
Pdx-1-Cre triple mutant animals, as well asKrasLSL-G12D/+;p48Cre com-
pound mutant, KrasLSL-G12D/+;Dpc4/Smad4flox/+;p48Cre triple mutant,
KrasLSL-G12D/+;Dpc4/Smad4flox/flox;p48Cre quadruple mutant, and vari-
ous littermate control animals on a mixed BlSwiss/129/SvJae/C57Bl/6
background. All studies were conducted in compliance with the Fred
Hutchinson Cancer Research Center IACUC guidelines.
Histopathology, Immunohistochemistry, Immunoblots,
and In Vitro Analyses
Detailed descriptions for these procedures are provided in the
Supplemental Data.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, ten supplemental figures, and three supplemental tables and
can be found with this article online at http://www.cancercell.org/
cgi/content/full/11/3/229/DC1/.
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